Health Condition 1: N189- Chronic kidney disease, unspecified Health Condition 2: N189- Chronic kidney disease, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Intervention4: Nil: Nil
Control Intervention1: CKD Patients (Stage 3 5) Not Receiving Erythropoietin Therapy
: The comparator gr
Sponsors
JNMC
Eligibility
Inclusion criteria
Inclusion criteria: dult patients aged 18 to 60 years. 2. Diagnosed with Chronic Kidney Disease (CKD) Stage 3 to 5 (based on eGFR criteria). 3. Patients who are clinically stable and on regular follow-up for CKD.
Exclusion criteria
Exclusion criteria: Patients with uncontrolled hypertension or diabetes (which may independently affect cognition).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in cognitive performance as assessed by MMSE and MoCA scores from baseline to 3 months in CKD patients receiving erythropoietin therapy compared to those not receiving erythropoietinTimepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in haemoglobin levels from baseline to three months correlation between change in haemoglobin levels & change in cognitive scores MMSE & MoCA domain specific cognitive improvement on MoCA subscales & incidence of adverse events related to erythropoietin therapy Timepoint: 3 months | — |
Countries
India
Contacts
Public ContactPrajyot Sahebrao Kompelwar
Datta Meghe
Outcome results
None listed